Actavis will become Allergan to emphasize branded pharma focus

Two years and three names later, Actavis will reinforce its branded pharmaceuticals-led growth strategy by changing its name to Allergan when the company's $66bn acquisition of the Botox (onabotulinumtoxinA) maker closes within the next month or two.